Welcome to our dedicated page for Amphastar Pharmaceuticals news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharmaceuticals stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Established in 1996, Amphastar is known for developing, manufacturing, and marketing injectable and inhalation products using state-of-the-art, cGMP-compliant facilities. The company operates five manufacturing facilities across the United States, China, and Europe, along with a cutting-edge new drug research center.
Amphastar's core business revolves around producing approximately 15 injectable products, with a strong focus on both generic and branded drugs that target large markets with high technical barriers to entry. The company's comprehensive portfolio includes injectable, inhalation, and intranasal products, catering to hospitals and urgent care clinical settings. These products are distributed through group purchasing organizations and drug wholesalers, with the majority of revenue being generated in the United States.
The company leverages its longstanding relationships with major group purchasing organizations and drug wholesalers in the U.S. to establish significant market share quickly. Amphastar's finished pharmaceutical products and Active Pharmaceutical Ingredient (API) products are divided into two main segments: Finished Pharmaceutical Products and API Products.
Recent achievements for Amphastar include the acquisition of commercially successful products like BAQSIMI® and the strategic expansion of their diabetes portfolio. The company reported impressive financial results for the third quarter of 2023, with net revenues of $180.6 million and a GAAP net income of $49.2 million. The strong performance was driven by their diabetes portfolio and the newly acquired BAQSIMI®.
Amphastar's product development pipeline is robust, with multiple ANDAs and biosimilar products targeting significant market opportunities. The company also announced the FDA approval of Albuterol Sulfate Inhalation Aerosol, marking a milestone in their ability to develop complex generic inhalation products. This approval reflects Amphastar’s technological and manufacturing expertise, positioning the company for future growth.
Amphastar's commitment to quality and innovation is further demonstrated by their strategic acquisition and integration activities, focused on maximizing commercial potential and delivering high-quality pharmaceutical solutions. The company continues to enhance its pipeline with both generic and proprietary products, targeting products with large market sizes and high growth potential.
For more information, visit www.amphastar.com.
Amphastar Pharmaceuticals has received FDA approval for its Ganirelix Acetate Injection, a 250mg/0.5mL prefilled syringe, indicated for controlling premature LH surges in women undergoing ovarian hyperstimulation. This marks the company's fourth injectable peptide product approval, with plans for market launch in Q2 2022. The U.S. market for Ganirelix is valued at approximately $89 million as of the end of 2021. Amphastar's pipeline includes four ANDAs targeting a market size of $3.9 billion and several biosimilars and generics, enhancing its market position.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022. This event, featuring key executives including Bill Peters and Dan Dischner, is scheduled for 12:45 pm EST. The presentation will be accessible through Amphastar's website and available for 90 days post-event. Amphastar focuses on developing and marketing generic and proprietary injectable products. More details can be found on their website at ir.amphastar.com.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported net revenues of $120.9 million for Q4 2021, a 26% increase year-over-year. GAAP net income stood at $19.8 million or $0.39 per share. For the fiscal year, revenues totaled $437.8 million, up 25%, with GAAP net income of $62.1 million, reflecting the company's strong performance in higher-margin products like Primatene Mist and epinephrine. The company anticipates further growth with multiple pipeline milestones set for 2022.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will release its fourth-quarter 2021 results on March 10, 2022, after market close. A conference call discussing the financial results is scheduled for 2:00 p.m. Pacific Time. The company specializes in developing injectable, inhalation, and intranasal products, mainly used in hospital settings. Amphastar cautions that its forward-looking statements involve uncertainties and risks, and actual results may differ from expectations. Investors can access details on the company's website.
Amphastar Pharmaceuticals announced that the FDA has tentatively approved its ANDA for Vasopressin injection, a critical drug indicated for increasing blood pressure in adults with vasodilatory shock. The market for VASOSTRICT®, the branded equivalent, was approximately $856 million in U.S. sales as of September 30, 2021. Amphastar plans to manufacture its product in the U.S. The company has several additional products in its pipeline, targeting a combined market size of over $28 billion.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) participated in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021. Key executives, including CFO Bill Peters and V.P. of Corporate Communications Dan Dischner, engaged in an analyst-moderated fireside chat. The presentation will be available on Amphastar's website starting the same day at 10:00 AM EST and will remain accessible for 90 days. Amphastar focuses on developing and marketing injectable and inhalation products used in clinical settings. For more details, visit ir.amphastar.com.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced participation in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on November 18, 2021. Key executives, including Bill Peters and Dan Dischner, will present a pre-recorded session available at 8:00 am GMT. The event will be accessible for 90 days via the company's website. Amphastar specializes in developing and manufacturing generic and proprietary injectable and inhalation products, primarily for hospital and urgent care settings.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported a strong financial performance for Q3 2021, with net revenues reaching $112.2 million, up 34% from $83.4 million in Q3 2020. The GAAP net income was $29.5 million, or $0.59 per share. Key product drivers included Primatene Mist, epinephrine, and glucagon, showing substantial sales increases. The company also highlighted a robust pipeline with several products aimed at a combined market size exceeding $27 billion. The significant gain from the restructuring of its Chinese subsidiary contributed to non-operating income growth.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will announce its third-quarter 2021 results on November 8, 2021, after market close. The company will host a conference call at 2:00 p.m. PT to discuss the financial outcomes. Amphastar specializes in developing and marketing generic and proprietary injectable, inhalation, and intranasal products, primarily for hospital use. The call can be accessed via telephone or through the company’s investor website.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, at 2:00 PM ET. Key executives including CFO Bill Peters and Sr. VP Tony Marrs will participate in the presentation. A webcast will be available for viewing on Amphastar's website for 90 days post-event. Amphastar specializes in developing and marketing generic and proprietary injectable, inhalation, and intranasal products, primarily for clinical settings.
FAQ
What is the current stock price of Amphastar Pharmaceuticals (AMPH)?
What is the market cap of Amphastar Pharmaceuticals (AMPH)?
What does Amphastar Pharmaceuticals, Inc. specialize in?
Where are Amphastar’s manufacturing facilities located?
What are Amphastar’s main product segments?
What recent product approval has Amphastar received from the FDA?
How does Amphastar distribute its products?
What significant acquisition has Amphastar completed recently?
What are the financial highlights for Amphastar’s third quarter of 2023?
What is the focus of Amphastar’s product development pipeline?
Where can I find more information about Amphastar Pharmaceuticals?
What are some key products in Amphastar’s portfolio?
